Subscribe

Kwang Dong Pharmaceutical Co., Ltd. (009290.KS)

KRW6,180.00 +230.00 (+3.87%)
KR KSC Healthcare Drug Manufacturers - Specialty & Generic
Address Gasan Building
Seoul, KR
CEO Sung-Won Choi
Website ekdp.com
IPO 2000-01-04
ISIN KR7009290008

Explore sections of this company profile

Description

Established in Seoul, South Korea, in 1963, Kwang Dong Pharmaceutical Co., Ltd. functions as a diversified healthcare enterprise. The company is actively involved in the development and distribution of an extensive range of pharmaceutical products. This portfolio includes various over-the-counter (OTC) remedies addressing common ailments such as coughs and colds, eye care, liver conditions, mineral deficiencies, vitamin supplementation, circulatory health, and general wellness tonics. Complementing these are its prescription-only (ETC) medicines, which encompass treatments for a broad spectrum of medical needs, including diabetes, cardiovascular disorders, metabolic imbalances, digestive issues, immune system modulation, obesity, genitourinary and anal conditions, neurological and psychiatric disorders, pain and inflammation, infections, and anti-cancer therapies. Beyond pharmaceuticals, Kwang Dong offers health supplements and a diverse selection of beverages, ranging from general consumer drinks to functional and traditional health-focused options. The company also extends its operations to include the management of hospitals and facilitates widespread product distribution through various retail and wholesale channels, including discount stores, television home shopping, and online e-commerce platforms. Furthermore, Kwang Dong Pharmaceutical acts as a comprehensive MRO (Maintenance, Repair, and Operations) service provider, specializing in the procurement of raw materials, intermediate goods, and industrial consumables, with services extending to construction and international sourcing.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
KRW6,180.00 +230.00 (+3.87%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
237.1K
Beta
0.34
Float Shares
19.82M
Free Float %
54.1%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.27% -8.30% -12.53% -7.50% +25.21% +26.50% +36.03% +14.55% -19.39% -27.45% +270.00%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
6,180.00
Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
2.34
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +1.2% Q1'26: +8.8% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    -55.6% Q1'26: -7.5% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +2.4% Q1'26: -3.2% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +1.9% Q1'26: +1.8% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +2.7% Q1'26: +2.7% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +31.0% Q1'26: +26.4% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    6.45× Q1'26: 5.80× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.45) × ERP
WACC = 57% × Ke + 43% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 6,180.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana. 		Dec 2032
1 Rev. Ana.
Revenue
955.45B
est: 572.20B (+67.0%)
1.06T
est: 639.00B (+65.3%)
1.14T
est: 1.15T (-0.5%)
1.18T
est: 1.17T (+0.6%)
1.24T
est: 1.25T (-0.9%)
1.24T
est: 1.32T (-5.6%)
1.34T
est: 1.39T (-4.0%)
1.51T
est: 961.00B (+57.6%)
1.64T
est: 961.00B (+70.7%)
1.15T
1.15T – 1.15T
+19.4% YoY
1.17T
1.17T – 1.17T
+2.2% YoY
1.25T
1.25T – 1.25T
+6.5% YoY
1.32T
1.32T – 1.32T
+5.5% YoY
1.39T
1.39T – 1.39T
+5.8% YoY
961.00B
961.00B – 961.00B
-31.0% YoY
EBITDA
62.39B
est: 23.78B (+162.3%)
57.31B
est: 26.56B (+115.8%)
51.10B
est: 47.70B (+7.1%)
51.59B
est: 48.77B (+5.8%)
58.72B
est: 51.93B (+13.1%)
85.19B
est: 54.77B (+55.5%)
51.02B
est: 57.93B (-11.9%)
54.97B
est: 39.94B (+37.6%)
44.63B
est: 32.40B (+37.7%)
38.69B
38.69B – 38.69B
+19.4% YoY
39.56B
39.56B – 39.56B
+2.2% YoY
42.12B
42.12B – 42.12B
+6.5% YoY
44.43B
44.43B – 44.43B
+5.5% YoY
46.99B
46.99B – 46.99B
+5.8% YoY
32.40B
32.40B – 32.40B
-31.0% YoY
EBIT
52.36B
est: 17.67B (+196.3%)
42.78B
est: 19.74B (+116.8%)
35.81B
est: 35.44B (+1.0%)
34.18B
est: 36.24B (-5.7%)
39.99B
est: 38.58B (+3.6%)
65.55B
est: 40.70B (+61.1%)
36.98B
est: 43.04B (-14.1%)
42.07B
est: 29.68B (+41.7%)
30.10B
est: 23.15B (+30.0%)
27.64B
27.64B – 27.64B
+19.4% YoY
28.26B
28.26B – 28.26B
+2.2% YoY
30.09B
30.09B – 30.09B
+6.5% YoY
31.74B
31.74B – 31.74B
+5.5% YoY
33.57B
33.57B – 33.57B
+5.8% YoY
23.15B
23.15B – 23.15B
-31.0% YoY
Net Income
35.02B
est: 27.70B (+26.4%)
28.06B
est: 26.90B (+4.3%)
23.20B
est: 21.37B (+8.5%)
22.35B
est: 21.09B (+5.9%)
23.06B
est: 24.26B (-4.9%)
45.37B
est: 27.02B (+67.9%)
24.02B
est: 29.26B (-17.9%)
36.97B
40.48B
27.99B
27.99B – 27.99B
27.63B
27.63B – 27.63B
-1.3% YoY
31.77B
31.77B – 31.77B
+15.0% YoY
35.38B
35.38B – 35.38B
+11.4% YoY
38.32B
38.32B – 38.32B
+8.3% YoY
—
— – —
-100.0% YoY
SGA
110.89B
est: 62.87B (+76.4%)
130.71B
est: 70.21B (+86.2%)
133.07B
est: 126.09B (+5.5%)
121.37B
est: 128.92B (-5.9%)
128.84B
est: 137.26B (-6.1%)
124.25B
est: 144.78B (-14.2%)
137.24B
est: 153.12B (-10.4%)
233.85B
est: 105.58B (+121.5%)
154.30B
est: 104.23B (+48.0%)
124.47B
124.47B – 124.47B
+19.4% YoY
127.27B
127.27B – 127.27B
+2.2% YoY
135.50B
135.50B – 135.50B
+6.5% YoY
142.93B
142.93B – 142.93B
+5.5% YoY
151.16B
151.16B – 151.16B
+5.8% YoY
104.23B
104.23B – 104.23B
-31.0% YoY
EPS
868.00
est: 692.00 (+25.4%)
692.00
est: 672.00 (+3.0%)
572.00
est: 534.00 (+7.1%)
551.00
est: 527.00 (+4.6%)
581.72
est: 606.00 (-4.0%)
1,119.49
est: 675.00 (+65.9%)
584.68
est: 731.00 (-20.0%)
913.39
1,010.12
534.00
534.00 – 534.00
527.00
527.00 – 527.00
-1.3% YoY
606.00
606.00 – 606.00
+15.0% YoY
675.00
675.00 – 675.00
+11.4% YoY
731.00
731.00 – 731.00
+8.3% YoY
—
— – —
-100.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-18 B 3/5 1/5 3/5 4/5 2/5 2/5 4/5
2026-05-15 B+ 3/5 1/5 3/5 4/5 2/5 3/5 5/5
2026-05-14 B+ 3/5 1/5 3/5 4/5 2/5 3/5 5/5
2026-05-13 B+ 3/5 1/5 3/5 4/5 2/5 3/5 5/5
2026-05-12 B+ 3/5 1/5 3/5 4/5 2/5 3/5 5/5
2026-05-11 B+ 3/5 1/5 3/5 4/5 2/5 3/5 5/5
2026-05-08 B 3/5 1/5 2/5 3/5 2/5 3/5 5/5
2026-05-07 B 3/5 1/5 2/5 3/5 2/5 3/5 5/5
2026-05-06 B 3/5 1/5 2/5 3/5 2/5 3/5 5/5
2026-05-04 B 3/5 1/5 2/5 3/5 2/5 3/5 5/5
2026-04-30 B 3/5 1/5 2/5 4/5 1/5 3/5 5/5
2026-04-29 B 3/5 1/5 2/5 4/5 1/5 3/5 5/5
2026-04-28 B 3/5 1/5 2/5 4/5 1/5 3/5 5/5
2026-04-27 B 3/5 1/5 2/5 4/5 1/5 3/5 5/5
2026-04-24 B 3/5 1/5 2/5 4/5 1/5 3/5 5/5
2026-04-23 B 3/5 1/5 2/5 4/5 1/5 3/5 5/5
2026-04-22 B 3/5 1/5 2/5 4/5 1/5 3/5 5/5
2026-04-21 B 3/5 1/5 2/5 4/5 1/5 3/5 5/5
2026-04-20 B 3/5 1/5 2/5 4/5 1/5 3/5 5/5
2026-04-17 B 3/5 1/5 2/5 4/5 1/5 3/5 5/5
2026-04-16 B 3/5 1/5 2/5 4/5 1/5 3/5 5/5
2026-04-15 B 3/5 1/5 2/5 4/5 1/5 3/5 5/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
57.58B
OE per share TTM
1,375.80
Owner's Yield
15.15%
Maintenance CapEx ratio
93.97%
Maint CapEx / Avg PPE
12.8%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 26 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Kodex KOSPI 226490.KS 0.01% 61.0K 0.15%
2 Schwab International Small-Cap Equity ETF SCHC 0.01% 295.7K 0.06%
3 Vanguard FTSE All-World ex-US Small-Cap ETF VSS 0.00% 641.9K 0.06%
4 Dimensional - Emerging Markets Value ETF DFEV 0.00% 71.5K 0.46%
5 Dimensional - Emerging Markets ex China Core Equity ETF DEXC 0.00% 11.6K 0.56%
6 Dimensional Emerging Markets Sustainability Core 1 ETF DFSE 0.00% 19.7K 0.44%
7 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 155.8K 0.39%
8 Dimensional - Emerging Core Equity Market ETF DFAE 0.00% 141.1K 0.29%
9 Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO 0.00% 3.1K 0.22%
10 Vanguard FTSE Pacific ETF VPL 0.00% 165.2K 0.07%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
29.85M
Shares Outstanding
36.66M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Hyun-Sik Kim President and Director — male
Ju-Hoon Ahn Senior Managing Director and Director — male
Kwa-Kyun Mo President and Director — male
Sung-Won Choi Chairman & CEO — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic